Navigation Links
Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
Date:11/5/2007

ORLANDO, Fla., Nov. 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) and The Sinai Center for Thrombosis Research at Sinai Hospital of Baltimore today announced results of the recently completed CLEAR PLATELETS 2 (Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets) study, showing that INTEGRILIN(R), a potent glycoprotein (GP) IIb- IIIa inhibitor, significantly inhibited platelet aggregation when added to bivalirudin, compared to bivalirudin alone, in patients undergoing elective coronary stenting. Results were presented at the American Heart Association Scientific Sessions in Orlando, FL.

CLEAR PLATELETS 2, designed to evaluate the effects of the addition of INTEGRILIN(R) to an antithrombotic regimen of aspirin, clopidogrel and bivalirudin in elective PCI patients, demonstrated that when added to bivalirudin, INTEGRILIN(R) significantly decreased platelet aggregation in response to multiple stimuli, thereby producing increased platelet inhibition. Results were statistically significant for all measurements of platelet aggregation induced by multiple agonists.

"The results reflect the importance of a GP IIb-IIIa inhibitor in reducing platelet aggregation," said Paul Gurbel, MD, Director of The Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore; Associate Professor at Johns Hopkins University, and principal investigator for the CLEAR PLATELETS 2 study. "This pharmacodynamic study supports the role of inhibition of platelet aggregation in patients undergoing elective coronary stenting," added Dr. Gurbel.

About CLEAR PLATELETS 2

CLEAR PLATELETS 2 was a randomized two-center, open label study enrolling 200 patients undergoing elective PCI wit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... US Phase II Clinical Trials for Organ Transplantation, ... announces positive Phase I clinical results for,its transplantation ... clinical trials for organ transplantation. , Today LifeCycle ... I clinical trial program of LCP-Tacro, a,proprietary, once-daily ...
... Hemispherx Biopharma, Inc.,(AMEX: HEB), a biopharmaceutical company ... new drug entities for pandemic,disease threats, announced ... therapeutic product candidate Alferon-LDO in,combating highly pathogenic ... Alferon-LDO is a low-dose experimental oral formulation,of ...
Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 2Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 4
(Date:9/16/2014)... (PRWEB) September 16, 2014 SAMHSA, the federal ... mission a reduction of the impact of substance abuse and ... on the SAMHSA website in September is National Recovery Month, ... honor the gains made by those individuals in recovery. ... to addiction treatment in an effort to help those with ...
(Date:9/16/2014)... Using a pain clinic as a testing ground, researchers ... first popularized by Toyota in Japan can substantially reduce ... interns and residents. , In a report on the ... Medicine , the researchers adopted the so-called "Just-in-Time" training ... service industries to stem waste and keep complicated operations ...
(Date:9/16/2014)... R.I. (PRWEB) September 16, 2014 As ... Sunday, Sept. 14, through Saturday, Sept. 20, Amica ... sure children are safe and secure while in the ... the National Traffic Highway Safety Administration (NHTSA), 20 ... not read the instruction manual when installing child restraints. ...
(Date:9/16/2014)... 2014 Regulatory intelligence (RI), the ... has become a crucial skill for regulatory professionals ... sectors. Regulatory Intelligence 101 , new from ... serves as an essential guide to the basics ... examines available regulatory intelligence tools, both free and ...
(Date:9/16/2014)... Illegal drug use among teens in the United States is ... Encouragingly, the new study also found that alcohol use, ... people between the ages of 12 and 17 also dropped ... people aged 12 and older across the United States revealed ... among this age group also dropped from 8.9 percent to ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 2Health News:Narconon Arrowhead Booklet Offers Tips During Recovery Month 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:RAPS Publishes Regulatory Intelligence 101 Book 2Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2
... apply the chemicals, study shows , THURSDAY, June 18 ... the normal risk of developing a precancerous blood disorder, ... undetermined significance) and characterized by an abnormal level of ... can lead to multiple myeloma, a cancer of the ...
... ... term, the continent’s healthcare leadership must be strengthened and expanded at the individual, institutional, ... ... -- To improve health outcomes in Africa over the long term, the continent’s healthcare ...
... up at night worrying whether they are going to develop diabetes ... middle age is a lifetime away. As it ... School of Medicine have found that young adults (18 to 30 ... treadmill test -- are two to three times more likely to ...
... Arnhem, June 2009 The 4th ESU Master class ... the European School of Urology (ESU) on 27-28 June ... The format consists of three modules. Module 1 is ... ,Immunotherapy and targeted therapies, and module 3 ,Systemic cytotoxic ...
... (OTC Bulletin Board: BHRT) a company committed to delivering ... treat heart failure and cardiovascular diseases announced today that ... systems at the American Association of Heart Failure Nurses ... place from June 25 - 27, 2009 at the ...
... , ... present never-before released results from two annual surveys at the upcoming DIA Meeting in ... ... for clinical trials information, will present never-before released results from two annual surveys aimed ...
Cached Medicine News:Health News:Pesticides Linked to Blood Disorder 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 2Health News:Accordia Global Health Foundation Calls for Greater Investment to Build African Healthcare Leadership 3Health News:Aerobically unfit young adults on road to diabetes in middle age 2Health News:4th ESU master class on medical treatment for urological cancer held in Barcelona, Spain 2Health News:Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 2Health News:Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 3Health News:CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting 2
Lombart clip-on occluder...
9 inch double ended with one end black and the other end with 49 holes...
Double Ended Occluders...
Long handle occluders are approximately 9 inches long....
Medicine Products: